|
Wednesday, June 12 |
|
|
|
|
|
6:00 PM |
|
Conference Registration |
|
|
|
|
|
8:00 PM |
|
Welcome Reception and Dinner |
|
|
|
|
|
Thursday, June 13 |
|
|
|
|
|
7:30 AM |
|
Breakfast |
|
|
|
|
|
8:50 AM |
|
Welcome and Opening Remarks |
|
|
|
|
|
SESSION I |
|
Complement in cancer: molecular insights and therapeutic concepts Chairs: Cecilia Garlanda and Ruben Pio |
|
9:00 AM |
1 |
Complementing the Cancer-Immunity Cycle Ruben Pio |
|
9:20 AM |
2 |
DuoHexaBody®-CD37, a Novel CD37-targeting Bispecific Antibody with a Hexamerization-enhancing Mutation, employs Complement Dependent Cytotoxicity (CDC) to Kill Patient-derived Chronic Lymphocytic leukemia (CLL) cells with unprecedented potency Ronald Taylor, Margaret Lindorfer, Simone Oostindie, Erika Cook, Clive Zent, Richard Burack, Frank Beurskens, Paul Parren, Janine Schuurman, and Esther Breij |
|
9:40 AM |
3 |
Pro-tumoral role of Complement activation in murine sarcoma models Elena Magrini and Cecilia Garlanda |
|
10:00 AM |
4 |
Targeting the complement system to improve radiotherapy Monica Olcina, Stavros Melemenidis, Ryan Kim, Dhanya Nambiar, Kerriann Casey, Rie von Eyben, Edward Graves, Quynh-Thu Le, Manuel Stucki, and Amato Giaccia |
|
10:15 AM |
5 |
Canonical and non canonical functions of C1q in cancer progression Marie Daugan, Rémi Noé, Carine Torset, Margot Revel, Isabelle Cremer, Catherine Sautès Fridman, Wolf Fridman, and Lubka Roumenina |
|
10:30 AM |
6 |
Anti gC1qR/p32/HABP1 monoclonal antibody therapy decreases tumor growth in an orthotopic xenotransplant model of triple negative breast cancer Ellinor Peerschke, Elisa de Stanchina, Katia Manova-Todorova, Anne Savitt, Qing Chang, Ning Fan, Afsar Barlas, Sho Fujisawa, and Berhane Ghebrehiwet |
|
10:50 AM |
7 |
Development of tumor models to study normal tissue radioprotection by C5aR1 inhibition Stavros Melemenidis, Monica Olcina, Ryan Kim, Amato Giaccia, and Edward Graves |
|
|
|
|
|
11:05 AM |
|
Coffee Break and Poster Viewing |
|
|
|
|
|
SESSION II |
|
Therapeutic development: novel complement inhibitors Chairs: Daniel Ricklin and Marta Biedzka-Sarek |
|
11:40 AM |
8 |
An update on the clinical development of the compstatin-based drug candidate AMY-101 John D. Lambris, Edimara Reis, Daniel Ricklin, George Hajishengallis, Dimitrios Mastellos, and Despina Yancopoulou |
|
12:00 PM |
9 |
Fragment based discovery of novel small molecules which bind and inhibit C1r Blake Rushing, Denise Rohlik, and Brandon Garcia |
|
12:15 PM |
10 |
Novel MASP-2 inhibitors developed via directed evolution of human TFPI1 are potent lectin pathway inhibitors Dávid Szakács, Andrea Kocsis, Róbert Szász, Péter Gál, and Gábor Pál |
|
12:30 PM |
11 |
A sialylated, truncated soluble CR1 with improved potency and pharmacokinetics in vivo Yun Dai, David Leong, Peter Soupourmas, Sandra Wymann, Tony Rowe, Adriana Bazmorelli, Helen Cao, and Matthew Hardy |
|
12:45 PM |
12 |
Therapeutic Targeting of Complement Component 5 (C5): From Zilucoplan, a Clinical-Stage Allosteric Peptide, to First-in-Class, Orally Bioavailable Small Molecule C5 Inhibitors Alonso Ricardo, Susan Ashwell, Petra Duda, Vincent Galullo, Ramin Farzaneh-far, Michelle Hoarty, Zhong Ma, Camil Sayegh, Kate Sherry, Yili Sun, Guo-Qing Tan, Jaya Tikhe, Douangsone Vadysirisack, Willmen Youngsaye, and Nanqun Zu |
|
1:00 PM |
13 |
SKY59 - a SMART C5 inhibitor Marta Biedzka-Sarek, Barbara Klughammer, Zenjiro Sampei, Alexandre Sostelly, Kenji Shinomiya, Angelika Jahreis, and Christoph Bucher |
|
1:20 PM |
14 |
Development of LNP023, an oral complement Factor B inhibitor Anna Schubart, Boerje Haraldsson, Julie Milojevic, Peter End and Irina Baltcheva |
|
1:35 PM |
15 |
“Ground control” of complement activation: Structure-activity relationship of the Factor H-binding peptide 5C6 Daniel Ricklin, Clément Bechtler, Sophia Koutsogiannaki, Christina Lamers, Katerina Zafirovska, Said Rabbani, Yiannis Sarigiannis, Avneesh Gautam, Yuji Teramura, Bo Nilsson, and John D. Lambris |
|
|
|
|
|
1:55 PM |
|
Lunch and informal Discussions |
|
|
|
|
|
7:30 PM |
|
Dinner and Informal Discussions Buses depart from the hotel lobby at 7:30 PM |
|
|
|
|
|
Friday, June 14 |
|
|
|
|
|
7:30 AM |
|
Breakfast |
|
|
|
|
|
SESSION III |
Structure, pathogens and mechanisms of multiple organ dysfunction Chairs: Suzan Rooijakkers and Brian Geisbrecht |
|
|
9:00 AM |
16 |
Order and disorder in complement activation studied by cryo-EM Gonzalo Obal Caballero and Piet Gros |
|
9:20 AM |
17 |
Exploring the functional consequences of conformational substates in C3b Brian Geisbrecht |
|
9:40 AM |
18 |
Antibody-mediated killing of bacteria by complement Seline Zwarthoff, L Aguinagalde, K Widmer, D Ugurlar, M Ruyken, G Vidarsson, F Beurskens, PC Aerts, CPM van Kessel, CJC de Haas, P Gros, D Ricklin, and Suzan HM Rooijakkers |
|
10:00 AM |
19 |
Structure-Function Relationships of Borrelial Classical Pathway-specific Complement Inhibitors Ryan Garrigues, Charles Booth, Denise Rohlik, Blake Rushing, and Brandon Garcia |
|
10:15 AM |
20 |
Relationship of Complement and Histones to Adverse Events in Polymicrobial Sepsis and Potential Therapeutic Interventions Peter Ward, Firas Zetoune, and Fatemeh Fattahi |
|
10:35 AM |
21 |
Complement C5a alters microvesicle shedding during polytrauma Ebru Karasu, Julia Demmelmaier, Rebecca Halbgebauer, and Markus Huber-lang |
|
|
|
|
|
10:50 AM |
|
Coffee Break and Poster Viewing |
|
|
|
|
|
SESSION IV |
Neurological and hemolytic disorders: targets and drug leads Chairs: Lubka Roumenina and Trent Woodruff |
|
|
11:30 AM |
22 |
Therapeutic inhibition of the complement system in diseases of the central nervous system Paul Morgan |
|
11:50 AM |
23 |
An evaluation of pharmacological tools for targeting the C5a receptor 1 (C5aR1) Trent Woodruff, Xiang Li, Declan Gorman, Avril Robertson, John Lee, and Richard Clark |
|
12:10 PM |
24 |
Safely Quenching Complement in Stroke Subtypes (SUCCESS) Trial E. Sander Connolly |
|
12:30 PM |
25 |
A protective role for complement C3aR activation in amyotrophic lateral sclerosis John Lee, Tanya McDonald, and Trent Woodruff |
|
12:45 PM |
26 |
Connecting monoclonal gammopathy to atypical hemolytic uremic syndrome Sophie Chauvet and Veronique Fremeaux-Bacchi |
|
1:05 PM |
27 |
Complement in intravascular hemolysis and sickle cell disease Lubka Roumenina |
|
1:25 PM |
28 |
Proximal complement inhibition for Paroxysmal Nocturnal Hemoglobinuria: it’s time to go Antonio Risitano |
|
|
|
|
|
1:45 PM |
|
Lunch and informal Discussions |
|
|
|
|
|
7:30 PM |
|
Dinner and Informal Discussions Buses depart from the hotel lobby at 7:30 PM |
|
|
|
|
|
Saturday, June 15 |
|
|
|
|
|
7:30 AM |
|
Breakfast |
|
|
|
|
|
SESSION V |
Mechanisms of activation, regulation and crosstalk Chairs: Anna Erdei and Peter Garred |
|
|
9:00 AM |
29 |
Regulation and inhibition of the lectin pathway of complement Peter Garred |
|
9:20 AM |
30 |
Cross-talk between the lectin and the alternative pathways of the complement system Péter Gál |
|
9:40 AM |
31 |
Crosstalk between innate elemens and B cell responses: Complement receptor type 1 (CD35) inhibits TLR and TLR+BCR dependent functions of human B lymphocytes Anna Erdei and Bernadett Mácsik-Valent |
|
10:00 AM |
32 |
Thiol Isomerase ERp57 targets and modulates the Lectin Pathway of Complement Activation Oskar Eriksson, Joyce Chiu, Philip Hogg, John Atkinson, M. Kathryn Liszewski, Robert Flaumenhaft, and Bruce Furie |
|
10:15 AM |
33 |
Oligomerisation of the complement regulator, properdin Ahmad Alzamami and Russell Wallis |
|
10:30 AM |
34 |
A direct link between complement and coagulation in thromboinflammation mediated by the lectin pathway Karin Fromell, Kristina Ekdahl, and Bo Nilsson |
|
10:45 AM |
35 |
Complement C5 and Toll-like receptor 4 play key roles in Escherichia coli-induced tissue factor upregulation on human monocytes and for plasma activation of coagulation Ole Brekke, Anne Landsem, Hilde Fure, Dorte Christiansen, Knut Lappegaard, Terje Espevik, and Tom Mollnes |
|
|
|
|
|
11:00 AM |
|
Coffee Break and Poster Viewing |
|
|
|
|
|
SESSION VI |
Complement in immune and inflammatory responses Chairs: Joerg Koehl and Kip Connor |
|
|
11:45 AM |
36 |
C5a activates vacuolated inflammatory eosinophils to drive experimental allergic asthma Anna Wiese, Katharina M Quell, Fanny Ender, Konstantina Antoniou, Torsten Schröder, Tillman Vollbrandt, Jing Sun, Ibrahim Osman, Franziska Hoffmann, Peter König, Markus Huber-Lang, Simon Hogan, Yves Laumonnier, and Jörg Köhl |
|
12:05 PM |
37 |
C3-targeted host modulation in periodontitis Hidetaka Ideguchi, Hui Wang, Kosuke Nagai, Tetsuhiro Kajikawa, Niki Moutsopoulos, John Lambris, and George Hajishengallis |
|
12:25 PM |
38 |
Higher gene copy number of complement C4B and elevated serum levels of complement are associated with hypertension and effective response of statins to reduce the progression of atherosclerosis in pediatric lupus Chack-Yung Yu, Evan Mulvihill, Stacy Ardoin, Susan Thompson, Bi Zhou, Gakit Yu, Emily King, Nora Singer, Deborah Levy, Hermine Brunner, Yee Ling Wu, Haikady Nagaraja, and Laura Schanberg |
|
12:40 PM |
39 |
Cholesterol crystals enhance NLRP3 activation in a complement dependent manner in coronary and carotid atherosclerosis Terje Espevik, Nathalie Niyonzima, Siril Bakke, Sverre Holm, Ida Gregersen, Øystein Sandanger, Hilde Orrem, Lars Gullestad, Geir Andersen, Jan Damås, Pål Aukrust, Bente Halvorsen, and Tom Mollnes |
|
12:55 PM |
40 |
Role of complement factor H-related protein 1 (FHR1) in sterile inflammation Sarah Irmscher, Silke Brix, Svante Zipfel, Luke Halder, Thorsten Wiech, Peter Zipfel, and Christine Skerka |
|
|
|
|
|
1:10 PM |
|
Lunch and informal Discussions |
|
|
|
|
|
3:30 PM |
|
City Tour Buses depart from hotel lobby at 3:30 PM |
|
|
|
|
|
7:30 PM |
|
Dinner and Informal Discussions Please note that buses do not pick-up at the hotel prior to dinner. Dinner proceeds right after the tour |
|
|
|
|
|
Sunday, June 16 |
|
|
|
|
|
7:30 AM |
|
Breakfast |
|
|
|
|
|
SESSION VII |
Targeting complement in ocular and renal indications Chairs: BaerbelRohrer and Veronique Fremeaux-Bacchi |
|
|
9:00 AM |
41 |
Retinal ischemia reperfusion injury is mediated by the alternative complement system Kip Connor |
|
9:20 AM |
42 |
Complement-directed Age-related Macular Degeneration is a Distinct Subset of the Disease: Gene-directed Therapeutics and Patient Stratification Will be Prudent Strategies for Future Clinical Trials Gregory Hageman, Burt Richards, Chris Pappas, Robert Anstadt, Jin Liu, Brandi Williams, Nathan Seager, Larry Wheeler, Karen Curtin, and Jill Hageman |
|
9:40 AM |
43 |
Age-related macular degeneration and innate immunity: molecular crosstalk between the complement system and the long pentraxin 3 Matteo Stravalaci, Mario Romano, Raffaella Parente, Marco Gobbi, Rita Gomes-Silva, Barbara Bottazzi, Alberto Mantovani, and Antonio Inforzato |
|
9:55 AM |
44 |
The Role of Complement in the Pathophysiology, Prevention, and Treatment of Antibody Mediated Rejection in Solid Organ Transplants Robert Montgomery |
|
10:15 AM |
45 |
The complex cellular basis of experimental complement-dependent acute kidney injury (AKI) Richard Quiggand Lee Chaves |
|
10:35 AM |
46 |
Fluid-phase activation of the complement alternative pathway in MGRS-C3G Yuzhou Zhangand Richard Smith |
|
|
|
|
|
10:50 AM |
|
Coffee Break and Poster Viewing |
|
|
|
|
|
SESSION VIII |
Complement biomarkers and diagnostics Chairs: Anna Blom and Brendan Keating |
|
|
11:20 AM |
47 |
Identifying Complement Activation Pathways in Individual Cells of Kidney-Transplant Patients undergoing Biopsies using Single-Cell RNA-Sequencing Brendan Keatingand Brian Piening |
|
11:40 PM |
48 |
ELISA assay for measurement of plasma C4d levels. Myriam Martin, Marcin Okroj, Anders Bengtsson, Andreas Jönssen, Karolina Smolag-Klosowska, Albin Björk, Tineke Kraaij, Sara Nilsson, Cees van Kooten, Onno Teng, Iva Gunnarsson, and Anna Blom |
|
12:00 PM |
49 |
Blood iC3b and iC3b:C3 ratio outperform traditional biochemical measures for monitoring disease activity and renal function in systemic lupus erythematosus (SLE) Al Kim, Vibeke Strand, Deepali Sen, John Fu, Nancy Mathis, Robin Bruchas, Nicholas Staten, Paul Olson, John Atkinson, and Martin Schmidt |
|
12:15 PM |
50 |
A comprehensive and sensitive bioanalytical platform for monitoring C3 activation and C3-targeted inhibitors in clinical samples Dimitrios Mastellos, Edimara S. Reis, Nadja Berger, Justin Gumas, Sarah Hughes, Avneesh Gautam, Daniel Ricklin, Despina Yancopoulou, and John D. Lambris |
|
12:35 PM |
51 |
Achievement of reliable results in complement research: Avoid the pitfalls by using appropriate methods and conditions. Tom Eirik Mollnes |
|
|
|
|
|
12:55 PM |
|
Closing Remarks |
|
|
|
|
|
1:10 PM |
|
Lunch and Informal Discussions |
|
|
|
|
|
8:00 PM |
|
Farewell Dinner |
|
|
|
|
|
Monday, June 17 |
|
|
|
|
|
7:30 AM |
|
Breakfast |
|
|
|
|
|
|
|
Departure |
|
POSTERS |
|
52 |
Truncated soluble Complement Receptor 1 sCR1[1392] shows improved in vitro potency compared to full-length sCR1 Matthew Hardy, Glenn Powers, Tony Rowe, Martin Spycher, and Sandra Wymann |
|
53 |
Complement Factor H, FHL-1 and Complement Factor H-related Proteins Exhibit Altered Activity and Competition That Dictate the Degree of Protection or Risk in Chromosome 1-directed Age-related Macular Degeneration Burt Richards, PhD, Jin Liu, PhD, Robert Anstadt, Jill Hageman, RN, Chris Pappas, and Gregory Hageman, PhD |
|
54 |
Simultaneous determination of activated C3 fragments and the terminal complement complex C5b-9 employing a label-free optical immunosensor Panagiota Petrou, Dimitrios Mastellos, Sotirios Kakabakos, Dimitrios Goustouridis, Ioannis Raptis, and John Lambris |